Targeting TEAD-ious resistance

Connor A Ott; Andrew E Aplin

doi:10.1016/j.trecan.2023.07.016

Targeting TEAD-ious resistance

Trends Cancer. 2023 Oct;9(10):780-781. doi: 10.1016/j.trecan.2023.07.016. Epub 2023 Aug 3.

Authors

Connor A Ott¹, Andrew E Aplin²

Affiliations

¹ Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
² Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: Andrew.Aplin@jefferson.edu.

PMID: 37543514
PMCID: PMC10530112 (available on 2024-10-01)
DOI: 10.1016/j.trecan.2023.07.016

Abstract

Recent advances in targeting mutant KRAS are limited by resistance. A recent study in Nature Cancer by Hagenbeek et al. utilizes a novel inhibitor that targets the TEAD transcription factor, GNE-7883, to overcome resistance to KRAS inhibitors. Thus, TEAD inhibitors may maximize the durability of KRAS inhibitors in patients with cancer.

Keywords: G12C; KRAS; TAZ; TEAD; TEAD inhibitor; YAP; drug tolerance; resistance.

MeSH terms

Humans
Models, Molecular
Neoplasms* / drug therapy
Neoplasms* / genetics
Proto-Oncogene Proteins p21(ras)*
Transcription Factors / genetics
Transcription Factors / metabolism

Substances

Proto-Oncogene Proteins p21(ras)
Transcription Factors

Abstract

MeSH terms

Substances

Grants and funding